Effects of rosuvastatin on LDL-C concentration and incidence of cardiovascular events after percutaneous coronary intervention in patients with diabetes mellitus associated with mild -moderate renal insufficiency
10.11855/j.issn.0577-7402.2014.04.02
- Author:
Su-Zhen JI
1
Author Information
1. Department of Cardiology, General Hospital of Shenyang Command
- Publication Type:Journal Article
- Keywords:
Angioplasty;
Cardiovascular diseases;
Cholesterol;
Chronic;
Diabetes mellitus;
LDL-C;
Percutaneous coronary;
Renal insufficiency;
Rosuvastatin;
Transluminal;
Type 2
- From:
Medical Journal of Chinese People's Liberation Army
2014;39(4):259-264
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of short-term application of rosuvastatin on LDL-C concentration and the incidence of cardiovascular events after percutaneous coronary intervention (PCI) in patients with diabetes mellitus associated with mild-moderate renal insufficiency (MMRI). Methods From Dec. 2008 to Oct. 2011, 2998 patients were enrolled from 53 centers in China for a TRACK-D project. Of them, 1590 patients to receive PCI were selected for this trial and assigned to rosuvastatin group (n=808) and control group (n=782). Patients in rosuvastatin group were treated with 10mg rosuvastatin every evening for 2 days before and 3 days after intervention. Control patients did not receive statin treatment in the 2 days before and 3 days after the procedure. The levels of LDL-C in the serum were measured before and after 72 hours of interventional treatment. The cardiovascular event rate was recorded during hospitalization and follow-up of 30 days. Results The baseline data were not significantly different (2.56±0.81mmol/L vs 2.52±0.81mmol/L, P>0.05) between the two groups. At 72 hours after PCI, the LDL-C concentration was lower in rosuvastatin group than in control group (2.12±0.67mmol/L vs 2.61±0.67mmol/L, P<0.01). The difference in LDL-C between post- and pre-operation were -0.42±0.59mmol/L vs 0.09±0.54mmol/L in rosuvastatin group and control group respectively and statistically significant (P<0.01). During the hospitalization and follow-up period of 30 days, the incidence of cardiovascular events was lower in rosuvastatin group than in control group (3.3% vs 4.9%, P=0.127), without significant difference. Conclusion The short-term application of rosuvastatin during the perioperative period in the patients with diabetes mellitus associated with MMRI (stages 2-3) can reduce LDL-C concentration and the incidence of cardiovascular events.
